ASH Clinical Practice Guidelines
ASH Guidelines are developed by leading clinical, methodological, and patient experts through a rigorous process to review evidence and write actionable recommendations. Our state-of-the-art methodology ensures that they meet the highest standards for trustworthiness and transparency. Guideline panels are explicit about how recommendations were determined and open about the quality of evidence that factored into the final decision-making process.
Browse the existing guidelines below, and learn about guidelines currently in development, including those open for public comment.
Acute Lymphoblastic Leukemia in Adolescents and Young Adults (ALL in AYA)
Two ASH Clinical Practice Guidelines will cover the treatment of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.
Acute Myeloid Leukemia
Guidelines covering the treatment of acute myeloid leukemia in older adults. These guidelines update and augment the ASH AML guidelines published in 2020.
Amyloidosis
Two guidelines covering alternative screening and diagnostic tests and testing strategies during the initial evaluation and workup of amyloidosis, and the treatment of AL amyloidosis.
Aplastic Anemia
Guidelines for aplastic anemia covering diagnosis, transplant, medical management of immunosuppressive therapies for adult and pediatric populations.
Iron Deficiency Anemia
Guidelines scope and plan to be determined in 2024.
Immune Thrombocytopenia
Guidelines covering second-line therapies for ITP in adult populations . These guidelines will update and augment ASH ITP guidelines for adult and pediatric populations that were published in 2019.
Management of Cancer-Associated Anemia
Guidelines to address management of cancer-related anemia, in collaboration with the American Society of Clinical Oncology (ASCO).
Myelofibrosis
Guidelines scope and plan to be determined in 2024.
Sickle Cell Disease
Five ASH Sickle Cell Disease Guidelines covering cardiopulmonary and kidney disease, cerebrovascular disease, transfusion, transplantation, and pain management.
Venous Thromboembolism
Ten guidelines covering prophylaxis for medical patients, diagnosis, anticoagulation therapy, heparin-induced thrombocytopenia, pregnancy, pediatrics, treatment, cancer, thrombophilia, prophylaxis in surgical patients, and anticoagulation in COVID-19 patients.
Von Willebrand Disease
Two guidelines on the diagnosis and management of VWD, in collaboration with the International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF), and World Federation of Hemophilia (WFH).
Questions?
If you have questions or need assistance with any aspect of the guideline topic proposal form, please email [email protected].
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission